A Case of Arrhythmia-İnduced Cardiomyopathy: Fluctuations in The Left Ventricle Systolic Functions Due to the Treatment and Recurrence of Arrhythmia

Öz

Arrhythmia-induced cardiomyopathy (AIC) is a potentially reversible form of cardiomyopathy in which left ventricular (LV) dysfunction results from atrial or ventricular arrhythmias. Effective treatment of arrhythmia can lead to complete improvement and arrhythmia recurrence may cause rapid decline in LV systolic functions. We present an interesting case of AIC with fluctuations in LV systolic functions due to treatment and recurrence of arrhythmia over time. In our case, arrhythmia responsible for AIC was atrial flutter. Cardiac magnetic resonance imaging findings were also discussed.

Aritmi İlişkili Kardiyomiyopatili Bir Olgu: Aritminin Tedavisi ve Tekrarlamasından Kaynaklanan Sol Ventrikül Sistolik İşlevlerindeki Dalgalanmalar

Öz

Aritmi ilişkili kardiyomiyopati (AİK), sol ventrikül (SV) işlev bozukluğunun atriyal ya da ventriküler aritmilerden kaynaklandığı kardiyomiyopatinin potansiyel olarak geri dönüşlü bir formudur. Aritminin etkin tedavisi tamamen iyileşme sağlayabilir ve aritmi tekrarlaması SV sistolik işlevlerinde hızlı azalmaya sebep olabilir. Burada aritminin tedavisi ve tekrarlamasından dolayı SV sistolik işlevlerinde zaman içinde dalgalanmalar olan ilginç bir AİK olgusunu sunuyoruz. Olgumuzda AİK’den sorumlu aritmi atriyal flutter idi. Kardiyak manyetik rezonans inceleme bulguları da tartışıldı.

Anahtar Kelimeler

• Aritmi ilişkili kardiyomiyopati,atriyal flutter,sol ventrikül

Kaynakça

1. Kaynaklar 1. Sossalla S, Vollmann D. Arrhythmia-Induced Cardiomyopathy. Dtsch Arztebl Int 2018; 115: 335-41.
2. 2. Gopinathannair R, Etheridge SP, Marchlinski FE, Spinale FG, Lakkireddy D, Olshansky B. Arrhythmia‐induced cardiomyopathies: mechanisms, recognition, and management. J Am Coll Cardiol 2015; 66: 1714–28.
3. 3. Nerheim P, Birger-Botkin S, Piracha L, Olshansky B. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. Circulation 2004; 110: 247-52.
4. 4. Ling LH, Kalman JM, Ellims AH, Iles LM, Medi C, Sherratt C, et al. Diffuse ventricular fibrosis is a late outcome of tachycardia-mediated cardiomyopathy after successful ablation. Circ Arrhythm Electrophysiol 2013; 6: 697-704.
5. 5. Gupta S, Figueredo VM. Tachycardia mediated cardiomyopathy: pathophysiology, mechanisms, clinical features and management. Int J Cardiol 2014; 172: 40-6.
6. 6. Jeong YH, Choi KJ, Song JM, Hwang ES, Park KM, Nam GB, et al. Diagnostic approach and treatment strategy in tachycardia-induced cardiomyopathy. Clin Cardiol 2008; 31: 172–8.
7. 7. Fujino T, Yamashita T, Suzuki S, Sugiyma H, Sagara K, Sawada H, et al. Characteristics of congestive heart failure accompanied by atrial fibrillation with special reference to tachycardia-induced cardiomyopathy. Circ J 2007; 71: 936–40.
8. 8. Hasdemir C, Yuksel A, Camli D, Kartal Y, Simsek E, Musayev O, et al. Late gadolinium enhancement CMR in patients with tachycardia-induced cardiomyopathy caused by idiopathic ventricular arrhythmias. Pacing Clin Electrophysiol 2012; 35: 465–70.